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344The Contribution of Malglycemia to Mortality among
Allogeneic Hematopoietic Cell Transplant Recipients
Marilyn J. Hammer,1 Corey Casper,2,3,4 Ted A. Gooley,2,5 Paul V. O’Donnell,2,3
Michael Boeckh,2,3 Irl B. Hirsch3Allogeneic hematopoietic cell transplantation (HCT) continues to be associated with substantial rates of
nonrelapse mortality (NRM). Numerous factors influence glucose metabolism among HCT recipients. We
hypothesized that ‘‘malglycemia,’’ defined as hyperglycemia, hypoglycemia or increased glycemic variability,
is associated with increased mortality in HCT patients. In a retrospective cohort study Cox regression
was used to assess the association of malglycemia after transplant with day 200 NRM. A total of 66,062 blood
glucose (BG) measurements from 1175 adult allogeneic HCTrecipients between 2000 and 2005 at the Fred
Hutchinson Cancer Research Center were evaluated (median 0.55 values per patient-day, range: 0.09-3.62).
Overall, there were 215 cases of NRM by day 200 post-HCT and 601 deaths from any cause throughout
observation. After adjustment for previously identified factors associated with NRM, all 3 components of
malglycemia were associated with increased NRM when individually modeled as time-dependent covariates.
Specifically, the hazard ratio for death was 1.93 for BG .200 mg/dL (P 5 .0009) and 2.78 for BG .300
(P 5 .0004) compared with BG 101-150 mg/dL. A minimum BG #89 was associated with a risk of day
200 NRM 2.17 times that of a minimum BG .89 (P\.0001). The upper quartile of glucose variability was
associated with a 14.57-fold increase in risk of NRM by day 200 relative to the first quartile (P\.0001). These
retrospective data indicate that malglycemia is associated with mortality following HCT. The applicability of
these findings to other situations and whether correcting malglycemia in HCT can lead to reductions in mor-
tality remain to be determined.
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MortalityINTRODUCTION
Disordered glucose metabolism is associated with
increased risk of death amongpersonswithboth chronic
and acute medical illnesses [1-3]. Recently, efforts have
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6/j.bbmt.2008.12.488hospitalization, but results from clinical trials and retro-
spective analyses have demonstrated inconsistent find-
ings with intensive insulin therapy [2-4]. The first
prospective, randomized control trial in critically ill sur-
gery patients reported a 42% reduction in mortality [2],
but these results were not replicated in the same group’s
second study of critically ill medical patients [5]. Other
populations studied in randomized control trials includ-
ing those with acute myocardial infarction [6,7], and
more recently severe sepsis [8], havenot shown improve-
ments with intensive insulin therapy. Conversely, other
retrospective data have suggested benefits from im-
proved glucose control in the hospital [9,10].
There is also growing evidence that hypoglycemia
may have a profound detrimental effect on outcomes,
including death and length of stay, thus limiting the
efforts for meticulous glucose control in the hospital
[11]. Besides the known neuroglycopenic dangers of
seizures and coma, the data suggest that rates of ‘‘severe
hypoglycemia’’ (often defined in this literature as a
blood glucose less than 40 mg/dL) approximate 18%
in a research setting [5,8]. Whether this is a marker of
Biol Blood Marrow Transplant 15:344-351, 2009 345Malglycemia and Mortality in HCTpoor outcome or offsets any benefit from intensive
insulin therapy is unknown.
Glycemic variability, a measurement of glucose
instability, was recently shown to be a predictor of
mortality in critically ill patients [12]. There has also
been increased interest in evaluating the impact of gly-
cemic variability on the vascular outcomes of diabetes
[13]. It appears that oxidative stress is generated by
variable glucose levels [14] but at this time the role of
this process in the pathogenesis of micro- and macro-
angiopathy is unclear.
Despite impressive gains in the safety of HCT
over the last 20 years, nonrelapse mortality (NRM)
remains high. Major causes of NRM include infection,
organ toxicity, and graft-versus-host disease (GVHD).
Under the best of circumstances, NRM occurs in 10%
to 15% of HCT patients by 100 days and in 20% to
30% of patients by 2 to 3 years [15,16], and it is there-
fore important to identify modifiable factors that
could further reduce NRM. In contrast to critically
ill patient groups, little data exist regarding the relative
contribution of the components of malglycemia,
which we define as disordered glucose metabolism
consisting of hyperglycemia, hypoglycemia, or in-
creased glycemic variability, to infections or mortality
posttransplant.
Allogeneic HCT provides a novel setting in which
to examine the association between malglycemia
and outcome, as the population consists of patients
who are of closely monitored and expected to have
a high incidence of hyperglycemia, infections, and
mortality posttransplant. In this retrospective study,
we examined the association between disordered glu-
cose metabolism and the post-HCT outcomes of
infection and death among a cohort of 1175 patients
who underwent allogeneic HCT at a single transplant
center.METHODS
Patients
All patients 18 years of age and older undergoing
allogeneic HCT at the Fred Hutchinson Cancer
Research Center (FHCRC), Seattle, Washington,
were approached for participation in a study protocol
that allows for retrospective review of medical records;
. 90% of patients gave their consent. All patients who
consented and were undergoing their first HCT
between 2000 and 2005 who had$1 glucose measure-
ment between day 0 (time of receipt of stem cells) and
day 100 were included. This study received approval
by the FHCRC institutional review board.
Evaluation and Outcomes
Data including basic demographic characteristics,
details of HCT, and any available measurements ofblood glucose (BG, serum or plasma) level were
abstracted from the FHCRC HCT database. Bedside
capillary glucose values were not used in this analysis.
Serum and plasma glucose concentrations were deter-
mined using the central laboratory’s Beckman-Coulter
Synchron LX-20 automated chemistry analyzer. Infor-
mation on infections was obtained from 3 sources. All
bacteremias were identified through electronic records
from the microbiology laboratory. Data on cytomega-
lovirus reactivation and disease [17], invasive fungal
infections [18] and Gram-negative bacteremias [19]
were obtained through previously validated databases.Statistical Analysis
Cox regression was used to assess the association
between BG and outcome following HCT. Five glyce-
mic parameters were examined: individual BG values,
glycemic variability (measured by the standard devia-
tion of individual BG values), average BG value, mini-
mum BG value, and maximum BG value. BG values
between days 0 and 100 following HCT were consid-
ered, as this is a time period during which regular
BG measurements are taken because of the fact that
patients remain in the FHCRC system and are closely
monitored during this time window. Outcomes
included day 200 nonrelapse mortality (NRM), overall
mortality (OM), and fungal infection, cytomegalovirus
(CMV) disease, and Gram-negative infections by
day 130 post-HCT. Day 130 was chosen to allow
a 30-day incubation period for infection acquired by
day 100. For infections that could occur multiple times
in a given patient, an Andersen-Gill model was fit [20].
Unless otherwise specified, all models were adjusted
for severity of disease (low, intermediate, and high)
[21], patient age at HCT, type of donor (HLA-identi-
cal sibling versus alternate donors [unrelated, mis-
matched sibling, or nonsibling relative]), year of
transplant, and presence of grades 2-4 graft-versus-
host disease [22] (GVHD, modeled as a time-depen-
dent covariate). We consider GVHD (a post-HCT
factor) because its occurrence is associated with
increased NRM, and GVHD is treated with steroids,
which increases BG. Each glycemic parameter was
treated as a time-dependent covariate and modeled as
a continuous variable using a cubic spline with 5 knots
set (prior to data analysis) at the 5th, 25th, 50th, 75th,
and 95th percentiles [23]. Ninety-five percent confi-
dence intervals for the point estimates of hazard ratios
were estimated from the observed variance/covariance
matrix. In addition, each parameter was modeled as
a categoric variable. All reported P-values are 2-sided.
Those comparing nested regression models were
derived from the likelihood-ratio test (LRT), and
P-values from regression models were estimated from
theWald test. No adjustments were made for multiple
comparisons.
Table 1. Patient Characteristics and Blood Glucose
Descriptive Statistics
Characteristic N (percent of range)
Median age in years (range) 47.3 (18.0, 74.5)
Diagnosis
CML 185 (16%)
AML 434 (37%)
ALL 105 (9%)
MDS 269 (23%)
NHL 72 (6%)
CLL 33 (3%)
AA 23 (2%)
Other 54 (5%)
Severity of disease
Low 121 (10%)
Intermediate 438 (37%)
High 616 (52%)
Patient/donor CMV
Donor +/Recipient + 342 (29%)
+/2 311 (27%)
2/+ 152 (13%)
2/2 368 (31%)
Unknown 2 (0.17%)
Year of transplant
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Patients and Distribution of Glycemic
Measurements
The population examined consisted of 1175 adult
patients who received a first allogeneic HCT between
2000 and 2005 at the FHCRC. Patient characteristics
are shown in Table 1.
There were a total of 66,062 BG measurements
within 100 days following HCT. Descriptive statistics
from these measurements are summarized in Table 1.
Ninety-nine percent of patients had, on average, at
least 1 BG measurement every 4 days. One thousand
ninety-six patients (93%) were hyperglycemic (BG .
150 mg/dL) at least once over the course of observa-
tion. Additionally, 16% of patients (n 5 190) were
hypoglycemic (BG#70 mg/dL) at least once. Figure 1
shows the distribution of all BG measurements taken
across all patients.2000 209 (18%)
2001 171 (15%)
2002 185 (16%)
2003 204 (17%)
2004 210 (18%)
2005 196 (17%)
Conditioning
Ablative 943 (82%)
Nonablative 232 (18%)
GVHD prophylaxis
CSP, MTX 553 (47%)
Other 622 (53%)
Median number BG measurements
per patient (range)
52 (9, 227)
Median average BG per patient (range) 133 mg/dL (90, 284)
Median maximum BG per patient (range) 244 mg/dL (112, 1159)
Median minimum BG per patient (range) 83 mg/dL (26, 155)
Median standard deviation of BG values
per patient (range)
33.2 mg/dL (6.8, 143.7)
CML indicates chronic myeloid leukemia; AML, acute myeloid
leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic
syndrome;NHL, non-Hodgkin’s lymphoma; CLL, chronic lymphocytic leu-
kemia; AA, aplastic anemia; CMV, cytomegalovirus; CSP, cyclosporine;
MTX,methotrexate;GVHD, graft-versus-host disease; BG, blood glucose.Mortality as a Function of BG Parameters
Shown in Table 2 are correlation coefficients for
eachof thepossiblepairsof glycemicparameters consid-
ered.Given these correlations, in regressionmodels that
consider more than 1 glycemic parameter we did not
consider eithermaximumor averageBGif glycemic var-
iability was included. A total of 215 nonrelapse deaths
occurred by day 200.When considered alone, each gly-
cemic parameter was associated with a statistically sig-
nificantly increased risk of day 200 NRM (Table 2).
Each parameter including individual BG, mini-
mum BG, and glycemic variability, was significantly
associated with NRM in a model considering all 3
with each modeled continuously. We found a nonmo-
notonic association between individual BG values and
NRM, with hypoglycemia, hyperglycemia, and glyce-
mic variability all associated with an elevated hazard
of NRM (Figure 2a), although the association for BG
values below 103 mg/dL was not statistically signifi-
cant relative to this value, as evidenced by the 95%
confidence intervals (a BG of 103 mg/dL is the value
at which the modeled hazard of day 200 NRM reached
a minimum).
We also modeled the 3 glycemic parameters as
categoric variables. As shown in Table 3, glucose
values .200 mg/dL were associated with an approxi-
mately 2- or more fold increased risk of nonrelapse
death compared to values 101-150 mg/dL after con-
sideration of glycemic variability, minimum BG, and
the nonglycemic variables indicated (P\ .001). More-
over, a minimum BG\90 mg/dL (89 mg/dL was the
median minimum BG) was associated with a more
than 2-fold risk of NRM compared to a minimum
BGof 90mg/dL ormore (P\ .0001). Evenmore strik-
ing, the risk of death was up to 14-fold higher among
patients with the greatest variability in their BGmeasurements (the upper quartile of standard devia-
tions) compared to patients with lower variability
(the first quartile of standard deviations) (P\ .0001).
Virtually all patients who develop clinically signif-
icant grades 2-4 acute GVHD (aGVHD) receive
steroids for treatment of GVHD, whereas it is rare
for patients who do not develop GVHD to receive
steroids. Because steroid use leads to increased BG,
we examined the impact of grades 2-4 aGVHD on
the association of individual BG values with day 200
NRM. There was little suggestion that this association
was dependent on the presence of grades 2-4 GVHD
(P 5 .81, interaction test). Out of concern that BG
values in close proximity to death could be abnormal
as a result of the impending death (reduced hepatic
and renal gluconeogenesis), we also fit models that
excluded BG values that occurred within 2 days of
Figure 1. Distribution of BG values across all patients from days 0-100. Values\30 and.300 are assigned values of 30 and 300, respectively, for plot-
ting purposes.
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were unchanged (data not shown). In addition, the
association between variability and NRM appeared
to hold across all individual BG levels as well as mini-
mum BG values (P 5 .93, P 5 .22, respectively in
interaction tests).
There were 601 deaths from any cause over the
course of observation (range: 8-2365 days [0.02-
6.5 years]). Of the 574 survivors at last contact, the
median follow-up was day 1471 (4.0 years), range of
97-2741 days (0.3-7.5 years). The same qualitative
conclusions observed with day 200 NRM were seen
with overall mortality (Table 4).Infections as a Function of BG and Glycemic
Variability
Although there could be many explanations for the
observed association between malglycemia and post-
transplant mortality, infections are a common compli-
cation in both diabetes and HCT, and we therefore
sought to determine the relationship between malgly-
cemia and infection in HCT. FHCRC has developed
a database for invasive fungal infection, CMV disease,
and Gram-negative bacteremias, which are the leading
infectious complications in HCT. Combining theseTable 2. Association of Glycemic Parameters with Day 200 NonRel
Glycemic Parameter
Statistical Significanceof
Association with Day 200 NRM* Individual BG Value
Individual BG value P < .0001 —
Average BG value P < .0001
Glycemic variability P < .0001
Minimum BG P < .0001
Maximum BG P < .0001
BG indicates blood glucose; GVHD, graft-versus-host disease; HCT, hematopo
*Modeled as a continuous variable using a cubic spline, with P-value estimated
regression model adjusting for disease, age, type of donor, year of HCT, and ainfections into a composite infection endpoint, there
were 1073 episodes observed among 506 patients
(43%) who had at least 1 occurrence. Of these 506,
235 (46.4%) had a single episode, 112 (22.1%) patients
had 2, 61 (12.1%) had 3, and 80 (15.8%) had 4 or more
episodes. Each glycemic parameter was significantly
associated with infection rate in separate regression
models (P\ .0001 for each parameter) and in a model
that includes individual BG, minimum BG, and glyce-
mic variability (P\ .0001 for each parameter) (Table
5). Shown in Figure 2b, i-iii, are hazard ratios (HR)
of this composite infection endpoint as a function of
each of these parameters, each plot adjusting for
the 2 parameters other than the 1 depicted in the
graph. As with NRM, the risk of infection was greatest
among those with the most variable BG, greater than
2-fold higher when compared with those with the least
variation in BG measurements (P\ .001) (Table 5).DISCUSSION
Few studies have examined the association be-
tween glucose and hematopoietic stem cell outcomes
[24]. To our knowledge, this is the first report of gly-
cemic variability impacting mortality or infection inapse Mortality and Correlation between Glycemic Parameters
Correlation between Glycemic Parameters
Average BG Value Glycemic Variability Minimum BG Maximum BG
R 5 0.56 R 5 0.46 R 5 0.21 R 5 0.38
— R 5 0.77 R 5 0.29 R 5 0.69
— R 5 0.09 R 5 20.09
— R 5 20.08
—
ietic cell transplant.
from the likelihood ratio test. Each parameter is included in a separate
cute GvHD.
Figure 2. (a) Relationships between malglycemia and day 200 NRM. (i) HR of day 200 NRM as a function of BG relative to a value of 103 mg/dL (where
the hazard of NRM attains its minimum) after adjusting for glycemic variability and minimum BG. (ii) HR of day 200 NRM as a function of minimum BG
relative to a value of 90 mg/dL (the median minimum value) after adjusting for glycemic variability and individual BG value. Solid line represents the HR,
dotted lines represent point-wise 95% confidence limits. (iii) HR of day 200NRM as a function of glycemic variability (measured as the standard deviation)
relative to a value of 29 mg/dL (the median standard deviation) after adjusting for individual and minimum BG values. (b) Relationship between malgly-
cemia and composite infection endpoint. (i) HR of failure for the composite infection endpoint as a function of BG relative to a value of 103 mg/dL after
adjusting for glycemic variability and minimum BG. (ii) HR of day 200 NRM as a function of minimum BG relative to a value of 90 mg/dL (the median
minimum value) after adjusting for glycemic variability and individual BG value. Solid line represents the HR, dotted lines represent point-wise 95% con-
fidence limits. (iii) HR of day 200 NRM as a function of glycemic variability (measured as the standard deviation) relative to a value of 29 mg/dL (the
median standard deviation) after adjusting for individual and minimum BG values. Solid line represents the HR, dotted lines represent point-wise
95% confidence limits.
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refers to the spectrum of postprandial hyperglycemia
above normal but not yet over the threshold consid-
ered diabetes [25], we define the overall dysregulation
of glucose as ‘‘malglycemia.’’ This term includes all
3 components of glycemic abnormalities noted in
this study: hyperglycemia, hypoglycemia, and glucose
variability.
In our cohort of patients undergoing allogeneic
HCT, we found that all components of malglycemia
were associated with death. Hyperglycemia has been
associated with increased mortality in a number of
different settings, including cardiovascular surgery in
patients with diabetes [26] and critically ill trauma
patients [27]. Several mechanisms for this have been
postulated through the use of intensive insulin therapy,
which leads to a reduction of inflammation [28], animprovement in circulating lipid levels which could
have a direct effect on outcome [29], and by protecting
the endothelium by inhibition of excessive inducible
nitric oxide synthase [30].
Hyperglycemia also impairs immune function at
both cellular and humoral levels with stunting of gran-
ulocyte function [31], dysfunctional cell signaling (evi-
denced by perturbations in the expression of
proinflammatory cytokines), and suboptimal antibody
generation [31-34]. Future analyses will need to deter-
mine whether hyperglycemia impacts cancer relapse or
secondary malignancies in HCT recipients.
The mechanisms by which hypoglycemia might
lead to an increased risk of death are less clear.
Krinsley and Grover reported in a case-control study
of over 5300 patients that even 1 episode of BG below
40 mg/dL was an independent risk factor for death [4].
Table 3. Relationship between Hyperglycemia, Glycemic
Variability, Hypoglycemia and Day 200 NonRelapse Mortality
after Hematopoietic Cell Transplant
Glycemic Parameter Hazard Ratio* 95% Confidence Interval P-Value
Blood glucose value (mg/dL)
101-150 1 [reference] — —
0-70 2.40 0.87-6.66 .09
71-100 0.67 0.41-1.11 .12
151-200 1.39 0.96-2.00 .08
201-300 1.93 1.31-2.83 .0009
>300 2.78 1.58-4.92 .0004
Standard deviation of
blood glucose values (mg/dL)
0-18 1 [reference] — —
18-29 2.28 1.03-5.09 .04
29-49 4.83 2.22-10.50 <.0001
>49 14.57 6.83-31.06 <.0001
Minimum blood glucose (mg/dL)
>89 1 [reference] — —
0-89 2.17 1.59-3.03 <.0001
*Hazard ratio derived from a multivariable model with exposure vari-
ables defined categorically and adjusted for the following predictors:
severity of disease, patient age at hematopoietic cell transplant (HCT),
type of donor, year of HCT, presence of grades 2-4 acute graft-versus-
host disease.
Table 5. Relationship between Hyperglycemia, Glycemic
Variability, Hypoglycemia and the Composite Infection End-
point after Hematopoietic Cell Transplant
Glycemic Parameter Hazard Ratio* 95% Confidence Interval P-value
Blood glucose value (mg/dL)
101-150 1 [reference] — —
0-70 1.30 0.65-2.60 .47
71-100 0.71 0.57-0.89 .002
151-200 1.29 1.08-1.54 .004
201-300 1.02 0.81-1.30 .85
>300 0.90 0.57-1.43 .66
Standard deviation of
blood glucose values (mg/dL)
0-18 1 [reference] — —
18-29 1.15 0.90-1.46 .26
29-49 1.59 1.24-2.04 .0002
>49 2.03 1.57-2.64 <.0001
Minimum blood glucose (mg/dL)
0-89 1 [reference] — —
>89 1.41 1.20-1.67 <.0001
*Hazard ratio derived from a multivariable model with exposure vari-
ables defined categorically and adjusted for the following predictors: se-
verity of disease, patient age at hematopoietic cell transplant (HCT),
type of donor, year of HCT, presence of grades 2-4 acute graft-versus-
host disease.
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severe sepsis [5,8], and Brunkhorst et al [8] recently re-
ported that with intensive insulin therapy in a popula-
tion with severe sepsis, severe hypoglycemia was more
frequent, often life-threatening, and required pro-
longed hospitalizations. However, to our knowledge,
no study to date has reported hypoglycemia as a risk
factor for incident infection and there are certainly ad-
ditional ways by which hypoglycemia could lead to
death apart from infection. Although individual BG
values \103 mg/dL were associated with an
increased risk of day 200NRM compared to BG values
at this level, the association was not statistically signif-Table 4. Relationship between Hyperglycemia, Glycemic
Variability, Hypoglycemia, and Overall Mortality after Hema-
topoietic Cell Transplant
Glycemic Parameter Hazard Ratio* 95% Confidence Interval P-value
Blood glucose value (mg/dL)
101-150 1 [reference] — —
0-70 1.84 0.86-3.93 .12
71-100 0.78 0.62-0.99 .04
151-200 1.17 0.93-1.46 .17
201-300 1.69 1.29-2.22 .0002
>300 2.44 1.60-3.72 <.0001
Standard eeviation of
blood glucose values (mg/dL)
0-18 1 [reference] — —
18-29 1.22 1.03-5.09 .19
29-49 1.53 2.22-10.50 .007
>49 2.63 6.83-31.06 <.0001
Minimum blood glucose (mg/dL)
>89 1 [reference] — —
0-89 1.58 1.31-1.92 <.0001
*Hazard ratio derived from a multivariable model with exposure vari-
ables defined categorically and adjusted for the following predictors: se-
verity of disease, patient age at hematopoietic cell transplant (HCT),
type of donor, year of HCT, presence of grades 2-4 acute graft-versus-
host disease.icant (Figure 2a, i; the categoric modeling led to a sim-
ilar conclusion). However, our data also showed that as
the minimum BG achieved decreases, the hazard of
day 200 NRM increases, and in fact, relative to the
value of 89 mg/dL our model showed statistically sig-
nificant increases for values below roughly 60 mg/dL
(Figure 2a, iii). These data suggest that transplant
patients may have an overall poor tolerance to hypo-
glycemia. The potential benefits of improved glucose
control, therefore, might very well need to be balanced
against the risk of hypoglycemia.
Glucose variability has just recently been described
as a factor associated with morbidity and mortality
among persons with disordered glucose metabolism.
We found glucose variability to be strongly associated
with death and infection, and it had a larger impact
on the appropriate regression models than did individ-
ual BG value or minimum BG value. Our results are in
agreement with Egi et al. [12], who reported a similar
contribution of glucose variability on mortality in
critically ill patients. It is difficult to differentiate the
biologic impact of hyperglycemia from glucose vari-
ability, because hyperglycemia is strongly correlated
with variability (in fact, in our data the correlation
coefficient between the maximum BG attained
throughout observation and the standard deviation
of BG values throughout observation was 0.92).
Furthermore, variability of glucose is usually a sign
of insulin deficiency, which in turn, would require
the providers of these patients to replace more insulin,
leading to a greater risk of hypoglycemia. A major lim-
itation of this retrospective study is that we were not
able to measure insulin levels nor were we able to doc-
ument individual episodes of iatrogenic hypoglycemia
from administered insulin. However, it could be
350 Biol Blood Marrow Transplant 15:344-351, 2009M. J. Hammer et al.speculated that even without attaining hypoglycemic
levels, wide fluctuations in plasma glucose may result
in oxidative stress as one possible mechanism. In the
long term, this may lead to the vascular complications
of diabetes [13,35], but the ramifications of this oxida-
tive stress over shorter periods of hospitalization are
unknown.
This study had a number of other limitations.
First, as a nonrandomized retrospective study, data
analyses were based on abstracted medical records.
The timing and frequency of glucose measurements
may have varied by either the degree of patient illness,
history of malglycemia, or other unmeasured factors.
The etiologies of patient malglycemia can only be
speculated and there may be information bias. Most
importantly, we had no information about whether
patients had a history of diabetes mellitus or received
insulin or oral hypoglycemic agents. Many factors
are associated with mortality in HCT. Our models
included those that have been identified in previous
studies at FHCRC and elsewhere, but other factors
may have been overlooked. Because of these limita-
tions, although the data quite clearly show an associa-
tion between malglycemia and outcome, we do not
definitively know if the observed association is causal
or if malglycemia is a surrogate for something that
we were not able to measure, or if the observedmalgly-
cemia was because of more or less frequent monitor-
ing.
Our study raises a number of difficult questions,
paramount of which is the degree to which the level
of BG should be controlled among HCT patients. Al-
though the potential for hypoglycemia is concerning
with the institution of tight glycemic control, the judi-
cious use of insulin analogues [36] and the develop-
ment of real-time continuous glucose sensors [37]
would appear to make meticulous control in these
patients an achievable goal for the immediate future.
We conclude that malglycemia is associated with
both mortality and infection in the setting of HCT.
Relatively small increases and decreases in normal glu-
cose values appear to have a detrimental impact on
these outcomes. Given the limitations of the current
study cited above and the adverse outcomes reported
in some of the recent trials [8], however, definitive
proof of this association and whether correction of
malglycemia leads to improved outcome can only be
addressed with a randomized clinical trial. The mech-
anisms of how glucose itself and glucose variability
might contribute to outcomes in this population re-
quire further study.ACKNOWLEDGMENTS
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